
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Arcadia Biosciences Inc (RKDA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: RKDA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -59.96% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.47M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 13082 | Beta 0.88 | 52 Weeks Range 1.85 - 6.44 | Updated Date 02/18/2025 |
52 Weeks Range 1.85 - 6.44 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.77 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.29% | Operating Margin (TTM) -114.51% |
Management Effectiveness
Return on Assets (TTM) -44.71% | Return on Equity (TTM) -67.08% |
Valuation
Trailing PE - | Forward PE 36.63 | Enterprise Value 239952 | Price to Sales(TTM) 1.18 |
Enterprise Value 239952 | Price to Sales(TTM) 1.18 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA 0.62 | Shares Outstanding 1364940 | Shares Floating 1353720 |
Shares Outstanding 1364940 | Shares Floating 1353720 | ||
Percent Insiders 0.67 | Percent Institutions 10.74 |
AI Summary
Arcadia Biosciences Inc.: A Deep Dive
Company Profile:
Detailed history and background:
- Founded in 1993 by Eric Kawaler, originally named Agracetus.
- Pioneered the use of genomics and genetic engineering in agriculture.
- 2002: Renamed Arcadia Biosciences.
- 2014: IPO on NASDAQ.
- Focuses on developing and commercializing value-added food and agricultural products.
Core business areas:
- GoodWheat™: Non-GMO wheat with improved protein content and gluten functionality.
- Sonova™ Canola: Non-GMO, healthier canola oil with low saturated fat and high oleic acid content.
- VERITAS®: Non-browning apples for fresh-cut markets.
- Health and Wellness Products: High-value ingredients and functional foods.
Leadership and corporate structure:
- Raj Ketkar: President and CEO.
- 8-member board of directors.
- Headquartered in Davis, California.
Top Products and Market Share:
Top products:
- GoodWheat™: Targeting the $6 billion global wheat protein market.
- Sonova™ Canola: Targeting the $25 billion global canola oil market.
- VERITAS® apples: Targeting the $2.8 billion global fresh-cut apple market.
Market share:
- GoodWheat™: Emerging product, market share still developing.
- Sonova™ Canola: Has achieved commercial scale in the US, market share growing.
- VERITAS® apples: Leading non-browning apple variety in the US, with increasing adoption.
Performance against competitors:
- GoodWheat™: Competes with conventional wheat and other non-GMO wheat varieties.
- Sonova™ Canola: Competes with conventional and other healthier canola oil varieties.
- VERITAS® apples: Competes with other non-browning apple varieties and traditional apples.
Total Addressable Market:
- Global wheat market: $6 billion.
- Global canola oil market: $25 billion.
- Global fresh-cut apple market: $2.8 billion.
Financial Performance:
- Revenue: Steady growth in recent years, driven by commercialization of Sonova™ Canola and increasing adoption of VERITAS® apples.
- Net Income: Fluctuating, with losses in some years due to investments in R&D and product development.
- Profit Margins: Improving, but still negative overall.
- Earnings per Share (EPS): Negative in recent years.
Year-over-year comparison:
- Revenue: Growing.
- Net Income: Fluctuating.
- Profit Margins: Improving.
- EPS: Negative, but improving.
Cash flow and balance sheet:
- Cash flow: Negative in recent years due to investments in growth.
- Balance sheet: Improving, with increasing cash and equivalents.
Dividends and Shareholder Returns:
- Dividend history: No dividend payouts in recent years.
- Shareholder returns: Negative in recent years due to stock price decline.
Growth Trajectory:
- Historical growth: Revenue growth driven by commercialization efforts.
- Future projections: Positive, driven by expected market adoption of key products.
- Growth initiatives: New product launches, partnerships, and expansion into new markets.
Market Dynamics:
- Increasing demand for healthy and sustainable food products.
- Growing adoption of non-GMO and healthier ingredients.
- Technological advancements in agriculture.
Arcadia Biosciences Inc.'s positioning:
- Well-positioned to capitalize on market trends with its innovative products.
- Adaptable and responsive to changing consumer preferences.
Competitors:
- Key competitors:
- Bunge (BG): Leading agribusiness company.
- Archer Daniels Midland (ADM): Major food processing and ingredients company.
- Cargill (CARG): Global food and agriculture company.
- Bayer (BAYRY): Life sciences company with strong presence in agriculture.
- Market share: Varies by product category.
- Competitive advantages: Proprietary technology and non-GMO focus.
Potential Challenges and Opportunities:
Challenges:
- Intense competition from established players.
- Regulatory hurdles and consumer acceptance of biotechnology.
- Dependence on commercial success of key products.
Opportunities:
- Expanding into new markets and product categories.
- Forming strategic partnerships.
- Leveraging technological advancements.
Recent Acquisitions:
- 2021: Acquired NextGen Acquisition Corp., a SPAC, to become publicly traded.
- 2020: Acquired Verdesian Life Sciences, a provider of sustainable crop nutrition solutions, to expand its reach in the agriculture market.
AI-Based Fundamental Rating:
Rating: 6/10
Justification:
- Potential for strong growth with innovative products aligned with market trends.
- Strong leadership and intellectual property portfolio.
- Financial performance improving but remains negative.
- High-risk investment due to early stage and competitive landscape.
Sources and Disclaimers:
- Company website: https://arcadiabio.com/
- SEC filings: https://www.sec.gov/edgar/search/
- Market research reports
- News articles
Disclaimer: This information is for educational purposes only and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.
About Arcadia Biosciences Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2015-05-15 | CEO, President & Director Mr. Thomas J. Schaefer C.F.A. | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 21 | Website https://www.arcadiabio.com |
Full time employees 21 | Website https://www.arcadiabio.com |
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.